ibuprofen and Cancer of Lung studies

Research Excerpts

Excerpt	Relevance	Reference
"Regular aspirin use may decrease cancer risk by reducing chronic inflammation."	9.20	Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Chaturvedi, AK; Hildesheim, A; Katki, HA; Kemp, TJ; Lang Kuhs, KA; Loftfield, E; Pinto, LA; Purdue, MP; Safaeian, M; Shiels, MS; Trabert, B; Wentzensen, N, 2015)
"Regular aspirin use may decrease cancer risk by reducing chronic inflammation."	5.20	Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Chaturvedi, AK; Hildesheim, A; Katki, HA; Kemp, TJ; Lang Kuhs, KA; Loftfield, E; Pinto, LA; Purdue, MP; Safaeian, M; Shiels, MS; Trabert, B; Wentzensen, N, 2015)
" This study explores the dynamics of cellular entry of dendrimers and hyperbranched polymers alone, and in the complexed form with ibuprofen, into A549 human lung epithelial carcinoma cells using UV/Vis spectroscopy, flow cytometry and fluorescence microscopy."	3.72	Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. ( Bassett, D; Glibatec, M; Kannan, RM; Kannan, S; Kolhe, P; Lieh-Lai, M; Raykova, V, 2004)
"Ibuprofen may inhibit lung cancer progression."	2.73	Factors associated with human small aggressive non small cell lung cancer. ( Berg, CD; Church, TR; Freedman, MT; Hocking, WG; Hu, P; Kvale, PA; Oken, MM; Prorok, PC; Ragard, LR; Riley, TL; Tammemagi, CM, 2007)
"3 patients in the colorectal cancer group demonstrated objective responses (1 complete remission (CR), 2 partial remission (PR))."	2.68	Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. ( Braun, M; Engelhardt, R; Galanos, C; Mackensen, A; Mertelsmann, R; Otto, F; Schmid, P; Seiz, A; Wehr, U, 1996)
"Ibuprofen, therefore, is a potential therapeutic agent that might allow lowering the doses of cisplatin and limiting the many challenge associated with its toxicity and development of drug resistance."	1.40	Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. ( Endo, H; Kido, H; Okumura, Y; Yano, M, 2014)
" Pharmacokinetic studies in rats revealed that liposome-encapsulated PIA exhibited remarkable resistance to hydrolysis by carboxylesterases, remaining largely intact in the systemic circulation, and demonstrated selective distribution to the lungs."	1.40	A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies. ( Alston, N; Cheng, KW; Huang, L; Mattheolabakis, G; Nie, T; Ouyang, N; Papayannis, I; Rigas, B; Wong, CC, 2014)
" These agents were tested either alone for the prevention of metastasis or in combination with IL-2 for the eradication of established metastasis."	1.28	Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2. ( Chan, FP; Khoo, NK; Lala, PK; Saarloos, MN, 1992)

Research

Studies (12)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Death Rates From All Causes

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (33.33)	18.2507
2000's	5 (41.67)	29.6817
2010's	3 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Endo, H	1
Yano, M	1
Okumura, Y	1
Kido, H	1
Cheng, KW	1
Nie, T	1
Ouyang, N	1
Alston, N	1
Wong, CC	1
Mattheolabakis, G	1
Papayannis, I	1
Huang, L	1
Rigas, B	1
Lang Kuhs, KA	1
Hildesheim, A	1
Trabert, B	1
Kemp, TJ	1
Purdue, MP	1
Wentzensen, N	1
Katki, HA	1
Pinto, LA	1
Loftfield, E	1
Safaeian, M	1
Chaturvedi, AK	1
Shiels, MS	1
Kannan, S	2
Kolhe, P	2
Raykova, V	1
Glibatec, M	1
Kannan, RM	2
Lieh-Lai, M	2
Bassett, D	1
Khandare, J	1
Pillai, O	1
Harris, RE	1
Beebe-Donk, J	1
Alshafie, GA	1
Tammemagi, CM	1
Freedman, MT	1
Church, TR	1
Oken, MM	1
Hocking, WG	1
Kvale, PA	1
Hu, P	1
Riley, TL	1
Ragard, LR	1
Prorok, PC	1
Berg, CD	1
Bilodeau, JF	1
Wang, M	1
Chung, FL	1
Castonguay, A	2
Otto, F	1
Schmid, P	1
Mackensen, A	1
Wehr, U	1
Seiz, A	1
Braun, M	1
Galanos, C	1
Mertelsmann, R	1
Engelhardt, R	1
Hodgson, DM	1
Yirmiya, R	1
Taylor, AN	1
Jalbert, G	1
Khoo, NK	1
Chan, FP	1
Saarloos, MN	1
Lala, PK	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial[NCT00002540]		76,685 participants (Actual)	Interventional	1993-11-16	Active, not recruiting
Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal[NCT05751837]	Phase 1	6 participants (Anticipated)	Interventional	2023-03-16	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009.

Deaths From All Causes

Intervention	Deaths per 10,000 PY (Number)
Control	166.6
Prostate Screening	160.5

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009.

Prostate Cancer Death Rates

Intervention	Participants (Number)
Control	7089
Prostate Screening	6855

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate Cancer Deaths

Intervention	Deaths per 10,000 PY (Number)
Control	3.4
Prostate Screening	3.7

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate Cancer Incidence

Intervention	Participants (Number)
Control	145
Prostate Screening	158

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate Cancer Incidence Rates

Intervention	Participants (Number)
Control	3815
Prostate Screening	4250

Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test

Intervention	Diagnoses per 10,000 PY (Number)
Control	97.1
Prostate Screening	108.4

Number of positive screens with complications (NCT00002540)
Timeframe: One year from screening examination

T0 (Baseline) DRE Screening Results

Intervention	Positive screens w/ complications (Number)
	When DE Led to Prostate Cancer Diagnosis	When DE Did Not Lead to Prostate Cancer Diagnosis
Prostate Screening	901	124

Digital Rectal Examination (DRE) result. (NCT00002540)
Timeframe: T0 (at study entry)

T0 (Baseline) PSA Screening Results

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	30456	2481	1192

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T0 (at study entry)

T1 DRE Screening Results

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	31507	2718	22

Digital Rectal Examination (DRE) result. (NCT00002540)
Timeframe: T1 (one year after entry)

T1 PSA Screening Results

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	29311	2237	900

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T1 (one year after entry)

T2 DRE Screening Results

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	30159	2502	27

Digital Rectal Examination (DRE) results (NCT00002540)
Timeframe: T2 (two years after entry)

T2 PSA Screening Results

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	28391	2327	733

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T2 (two years after entry)

T3 DRE Screening Results

Intervention	Participants (Number)
	Negative	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	29063	2593	35

Digital Rectal examination (DRE) result (NCT00002540)
Timeframe: T3 (three years after entry)

T3 PSA Screening Results

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	27179	2317	748

Prostate-Specific Antigen (PSA) result (NCT00002540)
Timeframe: T3 (three years after entry)

T4 PSA Screening Result

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	27814	2676	43

Prostate-Specific Antigen (PSA) result (NCT00002540)
Timeframe: T4 (four years after entry)

T5 PSA Screening Results

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	20362	1796	12

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T5 (five years after entry)

Article	Year
Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015, Volume: 24, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Colorectal Neoplasms; Early Dete	2015
Factors associated with human small aggressive non small cell lung cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:10 Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Non-Small-Cell Lung; C	2007
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:10 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Toxins; Carcinoma, Non-Small-Cell Lu	1996

Article	Year
Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. Cell death & disease, 2014, Jan-30, Volume: 5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplati	2014
A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies. International journal of pharmaceutics, 2014, Dec-30, Volume: 477, Issue:1-2 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Stability; Huma	2014
Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. Journal of biomaterials science. Polymer edition, 2004, Volume: 15, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C	2004
Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload. Biomaterials, 2006, Volume: 27, Issue:4 Topics: Biocompatible Materials; Cell Line, Tumor; Dendrimers; Drug Delivery Systems; Humans; Ibuprofen; Lun	2006
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. International journal of biological sciences, 2007, Jun-13, Volume: 3, Issue:5 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Celecoxib; Chem	2007
Effects of nonsteroidal antiinflammatory drugs on oxidative pathways in A/J mice. Free radical biology & medicine, 1995, Volume: 18, Issue:1 Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Deoxyguanosine; Dinop	1995
Intracerebroventricular interleukin-1beta impairs clearance of tumor cells from the lungs: role of brain prostaglandins. Journal of neuroimmunology, 2001, Sep-03, Volume: 119, Issue:1 Topics: Adenocarcinoma; Animals; Brain; Cyclooxygenase Inhibitors; Diclofenac; Ibuprofen; Injections, Intrav	2001
Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer letters, 1992, Sep-14, Volume: 66, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Carcinogens; Drug Interac	1992
Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2. Clinical & experimental metastasis, 1992, Volume: 10, Issue:4 Topics: Adenocarcinoma; Animals; Cell Division; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Female	1992

ibuprofen and Cancer of Lung